ArticleOsteoarthritis and cartilage open2026
Movement smoothness and plasma proteomics are associated with functional impairment in knee osteoarthritis.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate clinical outcomes (performance-based tests and patient-reported outcome measures [PROMs]) and biomechanical measures of movement smoothness, and explore their associations with molecular markers in individuals with knee osteoarthritis (KOA). Method: Thirty-six individuals with KOA (mean age 62.7 years; 75% female) and 19 controls (mean age 62.3 years; 63% female) performed four functional tests: 10 m Fast-Paced Walk (10MWT), 30 s Sit-to-Stand (30STS), Single Leg Mini Squat (SLMS), and Jump for Distance. Movement smoothness during 30STS and SLMS was quantified using Spectral Arc Length (SPARC) from inertial sensors. Individuals with KOA completed PROMs, and pain was assessed in both groups. Proteomic profiling (Olink) identified differentially expressed proteins (DEPs). Results: Individuals with KOA showed poorer performance across all functional tests (p < 0.001-0.04) and higher pain (p < 0.001). SPARC metrics indicated reduced movement smoothness, with lower mean SPARC (p < 0.001-0.004) and higher variance (p < 0.001). Nine DEPs distinguished the KOA group: one upregulated (DEFB4A) and eight downregulated (FKBP5, CETN2, TBCB, AXIN1, PMVK, PTPN1, PRTFDC1, ST1A1). All downregulated proteins correlated positively with 30STS performance (|r| = 0.37-0.57), and three negatively with 10MWT (|r| = 0.36-0.40). Higher mean SPARC during 30STS correlated positively with these proteins and partially during SLMS. PROMs showed moderate associations with functional outcomes. Conclusion: Individuals with KOA exhibited impaired function, reduced movement smoothness, and distinct proteomic profiles. Associations between proteins and movement quality suggest a molecular link to neuromuscular function. Combining proteomics with objective movement analysis and PROMs may improve understanding of KOA heterogeneity and support patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.